drugset
Drugs / OSI-632
last change Jun 2019 re-read 2 minutes ago

OSI-632

also known as CP-547,632 · PAN-90806 · CP-632

Small molecule targets KDR via inhibition

Developed for
fallopian tube cancer · ovarian cancer · wet macular degeneration · diabetic retinopathy · lung cancer · primary peritoneal carcinoma · serous neoplasm
Investigated by
PanOptica, Inc. · Pfizer · Jonsson Comprehensive Cancer Center · National Cancer Institute (NCI)

Trials 6 · a red edge is where a trial was stopped

today NCT03479372 · Ph 1/2 NCT02475109 · Ph 1 NCT02022540 · Ph 1 NCT00096239 · Ph 2 NCT00074867 · Ph 2 NCT00074854 · Ph 1/2
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT02475109 Aug 2015 → May 2016 diabetic retinopathy PanOptica, Inc. Completed No outcome recorded
Phase 1 NCT02022540 Feb 2014 → Mar 2016 wet macular degeneration PanOptica, Inc. Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT03479372 Apr 2018 → May 2019 wet macular degeneration PanOptica, Inc. Completed No outcome recorded
Phase 1/2 NCT00074854 May 2002 → Mar 2005 lung cancer Pfizer Completed No outcome recorded
Phase 22 trials
Phase 2 NCT00096239 Dec 2004 → Feb 2005 fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma Jonsson Comprehensive Cancer Center Completed No outcome recorded
Phase 2 NCT00074867 Oct 2003 → Sep 2004 fallopian tube cancer, ovarian cancer, serous neoplasm Pfizer Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as OSI-632 ChEMBL registry synonym — accepted as the source's own label CHEMBL253969 ↗
Known as CP-547,632 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00074867 ↗
2

NCT00074854 ↗

NCT00096239 ↗
Known as CP-632 ChEMBL registry synonym — accepted as the source's own label CHEMBL253969 ↗
Known as PAN-90806 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03479372 ↗
2

NCT02475109 ↗

NCT02022540 ↗
Action Inhibit “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL253969 ↗
1

“VEGFR-2 tyrosine kinase inhibitor” NCT00074854 ↗
Modality Small molecule “an oral VEGFR-2 tyrosine kinase inhibitor” NCT00074854 ↗
Route Oral “an oral VEGFR-2 tyrosine kinase inhibitor” NCT00074854 ↗
Target KDR “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL253969 ↗